Related Experiment Video
Updated: May 23, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Rational Design and Organoid-Based Evaluation of a Cocktail CAR-γδ T Cell Therapy for Heterogeneous Glioblastoma
Guidong Zhu1, Zhongzheng Sun1, Yingchao Liu2
1Department of Neurosurgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250031, P.R. China.
Abstract:
Various challenges, including tumor heterogeneity and inadequate T cell infiltration, impede the progress of chimeric antigen receptor T cell (CAR-T) therapy for glioblastoma (GBM). To address these obstacles, a multiple step strategy is designed. Initially, literature review and bioinformatics analysis to screen a set of antigens that are heterogeneously expressed in GBM, which are designated as the target-bank, are leveraged. Then, according to the multiplex immunohistochemistry results of each patient's tumor sample, a personalized panel of antigens based on the principle that most cancer cells in tumor tissues can be covered from the target-bank is selected. To target these antigens, Vδ1 T cells are chosen as CAR vehicles because of its high tissue infiltration and off-the-shelf properties, and an optimized protocol for engineering CAR-Vδ1 T cells with high purity and cytotoxicity, low exhaustion, and cytokine release is developed. Next, the specific panel of cocktail CAR-Vδ1 T cells in the GBM organoids that are directly derived from the same patient's tumor is tested. The term "prof" cocktail therapy is coined to describe the approach using precise and rational combination of tumor antigens, organoid-based evaluation, and fitness of Vδ1 T cells. It may accelerate development of effective CAR-T drugs for heterogeneous solid tumors.
Insights
This study introduces a personalized chimeric antigen receptor T cell (CAR-T) therapy for glioblastoma (GBM) by selecting multiple tumor antigens and using Vδ1 T cells. This "prof" cocktail approach aims to overcome GBM heterogeneity and improve CAR-T efficacy in solid tumors.
Area of Science:
- Oncology
- Immunotherapy
- Biotechnology
Background:
- Chimeric antigen receptor T cell (CAR-T) therapy faces challenges in glioblastoma (GBM) due to tumor heterogeneity and poor T cell infiltration.
- Existing CAR-T approaches often struggle to effectively target the diverse antigen landscape of solid tumors like GBM.
Purpose of the Study:
- To develop a personalized and effective CAR-T therapy strategy for glioblastoma (GBM) by addressing tumor heterogeneity.
- To create a novel approach combining antigen selection, optimized Vδ1 T cells, and patient-specific organoid testing for improved CAR-T efficacy.
Main Methods:
- Literature review and bioinformatics analysis to establish a GBM antigen target bank.
- Personalized antigen panel selection based on patient tumor multiplex immunohistochemistry.
- Engineering of Vδ1 T cells as CAR vehicles, optimizing for infiltration, purity, cytotoxicity, exhaustion, and cytokine release.
- Testing of cocktail CAR-Vδ1 T cells in patient-derived GBM organoids.
Main Results:
- A strategy was designed to overcome GBM tumor heterogeneity and T cell infiltration challenges.
- Optimized CAR-Vδ1 T cells demonstrated high purity, cytotoxicity, and low exhaustion.
- Patient-derived GBM organoids were used for testing personalized CAR-T cell cocktails.
Conclusions:
- The developed "prof" cocktail therapy, integrating precise antigen selection, organoid evaluation, and Vδ1 T cell fitness, shows promise for treating heterogeneous solid tumors.
- This personalized approach may accelerate the development of effective CAR-T therapies for glioblastoma and other challenging cancers.
